Bristol Myers Squibb has exercised its option to extend its partnership with Evotec SE in the field of targeted protein degradation, triggering an undisclosed payment to Evotec. The companies initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates focusing on solid tumors.   The partnership leverages Evotec’s PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and ce...